<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1428">
  <stage>Registered</stage>
  <submitdate>8/01/2007</submitdate>
  <approvaldate>8/01/2007</approvaldate>
  <nctid>NCT00420823</nctid>
  <trial_identification>
    <studytitle>A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment</studytitle>
    <scientifictitle>A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SMRI Grant ID Number 06T-811</secondaryid>
    <secondaryid>MHREC 2006/040</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psychotic Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Taurine 4g

Placebo Comparator: Placebo pill - 4 placebo pills daily for 3 months

Experimental: Taurine 4g - Taurine 4g daily comprising four 1g pills


Treatment: drugs: Taurine 4g


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cognition (MATRICS Composite score) at 3 months</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Symptomatology at 3 months</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety at 3 months</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability at 3 months</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and females

          -  Between 18 and 25 years of age

          -  First Episode Psychosis

          -  Attending ORYGEN Youth Health, a geographical based catchment area service for young
             people aged between 15 and 25.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>25</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal
             lobe epilepsy, HIV encephalopathy)

          -  Mental retardation (unable and/or unlikely to give appropriate information of
             symptomatology or side-effects (IQ approximately lower than 80)

          -  History of clinically significant physical illness (e.g. terminal cancer, renal
             dialysis)

          -  History of brain surgery

          -  History of brain infarction

          -  Pregnant or lactating women or women of childbearing potential not using an acceptable
             method of contraception.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>121</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>ORYGEN Youth Health - Melbourne</hospital>
    <hospital>RAPPS programme, Southern Health - Melbourne</hospital>
    <postcode>3052 - Melbourne</postcode>
    <postcode>3168 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Stanley Medical Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Southern Health</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether Taurine 4g is effective with antipsychotic
      medication in the treatment of First Episode Psychosis.Taurine may have an effect on
      cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month
      period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00420823</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Colin P O'Donnell, MB,MRCPsych</name>
      <address>ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry,</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>